Medicare privatization plan would face Democratic resistance

A push by the Republican-controlled Congress to privatize Medicare won’t be supported with Democratic votes, according to House Democratic Leader Nancy Pelosi.

In an interview with Washington Post columnist Greg Sargent, Pelosi said if the hints from House Speaker Paul Ryan on privatization turn into real legislation, her caucus will be united against it. She compared it to what happened when President George W. Bush tried to privatize Social Security after the 2004 election.

“He gave us an opportunity by saying he would partially privatize Social Security. Everybody stuck together. The opportunity that we have now is the equivalent of the opportunity we had in ’05,” Pelosi said.

Ryan has falsely claimed Medicare is “going broke” because of the Affordable Care Act (ACA) and repealing that law would have to involve Medicare changes, including expanding Medicare Advantage or offering ACA-like subsidies to current beneficiaries to buy private insurance.

For more on how Pelosi expects Republicans to react to united opposition to a Medicare overhaul, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.